Moreover, there are other factors that influence the pharmacokinetics of oral P2Y12 inhibitors, especially in comatose patients of OHCA, such as mild therapeutic hypothermia (MTH), gastroparesis, hypoperfusion of gastrointestinal tract and platelet hyperreactivity as a result of systemic inflammatory response syndrome (SIRS) [37]. This evidence concerns the gene P2RY12 and systemic inflammatory response syndrome.